AbbVie Inc (ABBV)vsenVVeno Medical Corp (NVNO)
ABBV
AbbVie Inc
$211.32
-2.23%
HEALTHCARE · Cap: $360.63B
NVNO
enVVeno Medical Corp
$10.50
+0.57%
HEALTHCARE · Cap: $7.81M
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
NVNO
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.3%
Fair Value
$163.59
Current Price
$211.32
$47.73 premium
Intrinsic value data unavailable for NVNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : NVNO
The strongest argument for NVNO centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : NVNO
The primary concerns for NVNO are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVNO carries more volatility with a beta of 1.09 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
enVVeno Medical Corp
HEALTHCARE · MEDICAL DEVICES · USA
enVVeno Medical Corp is an innovative medical device company dedicated to transforming vascular access solutions for dialysis patients through its proprietary biocompatible technology. By addressing critical unmet needs in the dialysis sector, enVVeno enhances the safety and efficacy of vascular procedures, allowing it to capitalize on the growing vascular interventions market. The company's commitment to advanced engineering, coupled with stringent regulatory compliance, aligns it with the evolving healthcare landscape and reinforces its mission to improve patient outcomes in a vital area of medical care.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?